27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Genfit SA (NASDAQ:GNFT) has agreed to acquire the Swiss startup Versantis for CHF40 million upfront in a small-time buyout.
- The deal, which includes another CHF65 million in milestones, further consolidates the company's position as a leader in acute-on-chronic liver failure (ACLF).
- The deal is expected to close in the fourth quarter.
- Additionally, if Versantis' lead program is awarded an FDA priority review voucher, Genfit would be entitled to one-third of the funds from the potential sale.
- In December 2021, Genfit sold its lead NASH program to Ipsen SA (OTC:IPSEY) for up to €480 million.
- Versantis' lead candidate, VS-01, is central to the acquisition.
- A planned 60-patient Phase 2 Proof-of-concept trial of VS-01 in ACLF is expected to launch in the fourth quarter of 2022. Efficacy and safety interim data are expected as early as the first half of 2024.
- Versantis' platform works by draining toxins using liposomes. A solution containing "scavengers" is injected into a patient's abdomen, soaks up ammonia and other toxins, and is then drained.
- Versantis' follow-up program, VS-02, is an oral, small molecule designed to work similarly by minimizing ammonia absorption in patients with hepatic encephalopathy (HE).
- Price Action: GNFT shares are up 4.18% at $4.28 on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!